首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Evolution of Oseltamivir Resistance Mutations in Influenza A(H1N1) and A(H3N2) Viruses during Selection in Experimentally Infected Mice
【2h】

Evolution of Oseltamivir Resistance Mutations in Influenza A(H1N1) and A(H3N2) Viruses during Selection in Experimentally Infected Mice

机译:在实验感染小鼠中选择甲型流感病毒(A1H1)和甲型流感病毒(H3N2)的奥司他韦耐药突变的演变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The evolution of oseltamivir resistance mutations during selection through serial passages in animals is still poorly described. Herein, we assessed the evolution of neuraminidase (NA) and hemagglutinin (HA) genes of influenza A/WSN/33 (H1N1) and A/Victoria/3/75 (H3N2) viruses recovered from the lungs of experimentally infected BALB/c mice receiving suboptimal doses (0.05 and 1 mg/kg of body weight/day) of oseltamivir over two generations. The traditional phenotypic and genotypic methods as well as deep-sequencing analysis were used to characterize the potential selection of mutations and population dynamics of oseltamivir-resistant variants. No oseltamivir-resistant NA or HA changes were detected in the recovered A/WSN/33 viruses. However, we observed a positive selection of the I222T NA substitution in the recovered A/Victoria/3/75 viruses, with a frequency increasing over time and with an oseltamivir concentration from 4% in the initial pretherapy inoculum up to 28% after two lung passages. Although the presence of mixed I222T viral populations in mouse lungs only led to a minimal increase in oseltamivir 50% enzyme-inhibitory concentrations (IC50s) (by a mean of 5.7-fold) compared to that of the baseline virus, the expressed recombinant A/Victoria/3/75 I222T NA protein displayed a 16-fold increase in the oseltamivir IC50 level compared to that of the recombinant wild type (WT). In conclusion, the combination of serial in vivo passages under neuraminidase inhibitor (NAI) pressure and temporal deep-sequencing analysis enabled, for the first time, the identification and selection of the oseltamivir-resistant I222T NA mutation in an influenza H3N2 virus. Additional in vivo selection experiments with other antivirals and drug combinations might provide important information on the evolution of antiviral resistance in influenza viruses.
机译:在动物中通过连续传代进行选择期间,奥司他韦抗性突变的演变仍然很少被描述。在这里,我们评估了从实验感染的BALB / c小鼠肺部回收的A / WSN / 33(H1N1)和A / Victoria / 3/75(H3N2)流感病毒的神经氨酸酶(NA)和血凝素(HA)基因的进化在两代中接受次优剂量(0.05和1 mg / kg体重/天)的奥司他韦。使用传统的表型和基因型方法以及深度测序分析来表征耐奥司他韦变体的潜在突变选择和群体动态。在回收的A / WSN / 33病毒中未检测到耐奥司他韦的NA或HA变化。但是,我们在回收的A / Victoria / 3/75病毒中观察到I222T NA替代的阳性选择,其频率随时间增加,并且奥司他韦的浓度从初始治疗前接种物中的4%上升到两次肺部感染后的28%段落。尽管小鼠肺中混合的I222T病毒种群仅导致奥司他韦50%酶抑制浓度(IC50)与基线病毒相比最小增加(平均5.7倍),但表达的重组A /与重组野生型(WT)相比,Victoria / 3/75 I222T NA蛋白的oseltamivir IC50水平提高了16倍。总之,在神经氨酸酶抑制剂(NAI)压力下进行的一系列体内传代与时间深度测序分析的结合,首次实现了对H3N2流感病毒耐奥司他韦的I222T NA突变的鉴定和选择。使用其他抗病毒药物和药物组合进行的其他体内选择实验可能会提供有关流感病毒抗病毒耐药性演变的重要信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号